US Patent

US8071130 — Solid preparation

Formulation · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2028-06-08 · 2y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a solid preparation containing an insulin sensitizer and another active ingredient, with a specific coating to improve dissolution behavior.

USPTO Abstract

The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from “a solid preparation containing only an insulin sensitizer as an active ingredient”. The solid preparation comprises “a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol” and “a part containing an active ingredient other than an insulin sensitizer”.

Drugs covered by this patent

Patent Metadata

Patent number
US8071130
Jurisdiction
US
Classification
Formulation
Expires
2028-06-08
Drug substance claim
No
Drug product claim
Yes
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.